Literature DB >> 11098767

Percutaneous endopyelotomy.

S B Streem1.   

Abstract

Percutaneous endopyelotomy, introduced over 15 years ago, is a well-established alternative to open operative pyeloplasty for management of ureteropelvic junction (UPJ) obstruction. Although several variations of the technique have been described, the goal in all cases is to develop a full thickness incision though the obstructing proximal uretra that extends out to the peripyeloureteral fat and heals over an internal stent. Though a percutaneous endopyelotomy can be considered for almost any patient with primary or secondary UPJ obstruction, it is particularly valuable in the setting of upper tract stones that can then be managed simultaneously. This article reviews the indications, techniques, and outcomes of percutaneous endopyelotomy.

Entities:  

Mesh:

Year:  2000        PMID: 11098767     DOI: 10.1016/s0094-0143(05)70118-x

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  5 in total

Review 1.  Antegrade percutaneous endopyelotomy.

Authors:  Raymond Ko; Mordechai Duvdevani; John D Denstedt
Journal:  Curr Urol Rep       Date:  2007-03       Impact factor: 3.092

2.  Percutaneous nephroscopic surgery.

Authors:  Tae-Kon Hwang
Journal:  Korean J Urol       Date:  2010-05-19

3.  The role of percutaneous endopyelotomy for ureteropelvic junction obstruction.

Authors:  N J Rukin; D A Ashdown; P Patel; S Liu
Journal:  Ann R Coll Surg Engl       Date:  2007-03       Impact factor: 1.891

Review 4.  Management of ureteropelvic junction obstruction in adults.

Authors:  Fahd Khan; Kamran Ahmed; Nikiesha Lee; Ben Challacombe; Mohammed S Khan; Prokar Dasgupta
Journal:  Nat Rev Urol       Date:  2014-10-07       Impact factor: 14.432

5.  Laparoscopic pyeloplasty and flexible nephroscopy: simultaneous treatment of ureteropelvic junction obstruction and nephrolithiasis.

Authors:  Adam J Ball; Raymond J Leveillee; Vipul R Patel; Carson Wong
Journal:  JSLS       Date:  2004 Jul-Sep       Impact factor: 2.172

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.